Elsevier obtains cancer drug compendia
Scientific publisher announces definitive agreement to purchase Tampa, Fla.-based Gold Standard, Inc. a provider of drug and clinical information at the point of care. Gold Standard CEO Russ Thomas will continue to lead the organization as part of Elsevier, according to an April 19 release by both firms. With the purchase, Elsevier gains Gold Standard's eMPOWERx electronic prescribing tool and off-label oncology drug compendia currently in development. The deal comes as Medicare considers approving additional compendia for local carriers to use when making off-label coverage decisions [Editor's note: "The Pink Sheet" is published by Elsevier subsidiary F-D-C Reports]...
You may also be interested in...
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.
The company is optimistic about a significant portion of eligible patients opting for its newly approved long-acting HIV therapy over daily, oral antiviral therapy.